Evidence map›Paper›PMID 38600506›Full record

ArticleJournal of nanobiotechnology2024

A thermoresponsive nanocomposite integrates NIR-II-absorbing small molecule with lonidamine for pyroptosis-promoted synergistic immunotherapy.

Pengfei Chen, Chi Zhang, Liuliang He, Mingfei Li, Jie Rong, Pengfei Sun, Yingying Chen, Daifeng Li

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nanobiotechnology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Pengfei ChenDepartment of Orthopedics, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China.
Chi ZhangDepartment of Orthopedics, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China.
Liuliang HeDepartment of Orthopedics, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China.
Mingfei LiDepartment of Orthopedics, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China.
Jie RongState Key Laboratory of Organic Electronics and Information Displays & Institute of Advanced Materials (IAM), Jiangsu Key Laboratory for Biosensors, Nanjing University of Posts & Telecommunications, Nanjing, 210023, China.
Pengfei SunState Key Laboratory of Organic Electronics and Information Displays & Institute of Advanced Materials (IAM), Jiangsu Key Laboratory for Biosensors, Nanjing University of Posts & Telecommunications, Nanjing, 210023, China. iampfsun@njupt.edu.cn.
Yingying ChenDepartment of Gynecology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China. chenyingying_zzu@163.com.
Daifeng LiDepartment of Orthopedics, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China. lidaifeng@zzu.edu.cn.

Funding

Natural Science Fund for Excellent Young Scholars of Henan Province 232300421050the National Natural Science Foundation of China 82102588Young Elite Scientists Sponsorship Program by China Association for Science and Technology 2023QNRC001Youth Talent Promotion Project of Henan Province 2023HYTP042
6 · The paper itself

Abstract

Photothermal immunotherapy is regarded as the ideal cancer therapeutic modality to against malignant solid tumors; however, its therapeutic benefits are often modest and require improvement. In this study, a thermoresponsive nanoparticle (BTN@LND) composed of a photothermal agent (PTA) and pyroptosis inducer (lonidamine) were developed to enhance immunotherapy applications. Specifically, our "two-step" donor engineering strategy produced the strong NIR-II-absorbing organic small-molecule PTA (BTN) that exhibited high NIR-II photothermal performance (ε

Indexed as

IndazolesNanoparticlesNeoplasmsCell Line, TumorHumansImmunotherapyPhototherapyPyroptosisIndazoleslonidamineDonor engineeringNIR-II absorptionOrganic photothermal agentsPhotothermal immunotherapyPyroptosis

Identifiers

PMID38600506
PMCPMC11007887

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.